Cargando…
A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
Background: To investigate whether the radiomics signature (Rad-score) of DCE-MRI images obtained in triple-negative breast cancer (TNBC) patients before neoadjuvant chemotherapy (NAC) is associated with disease-free survival (DFS). Develop and validate an intuitive nomogram based on radiomics signa...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632946/ https://www.ncbi.nlm.nih.gov/pubmed/34868273 http://dx.doi.org/10.3389/fgene.2021.783513 |
_version_ | 1784607851097882624 |
---|---|
author | Xia, Bingqing Wang, He Wang, Zhe Qian, Zhaoxia Xiao, Qin Liu, Yin Shao, Zhimin Zhou, Shuling Chai, Weimin You, Chao Gu, Yajia |
author_facet | Xia, Bingqing Wang, He Wang, Zhe Qian, Zhaoxia Xiao, Qin Liu, Yin Shao, Zhimin Zhou, Shuling Chai, Weimin You, Chao Gu, Yajia |
author_sort | Xia, Bingqing |
collection | PubMed |
description | Background: To investigate whether the radiomics signature (Rad-score) of DCE-MRI images obtained in triple-negative breast cancer (TNBC) patients before neoadjuvant chemotherapy (NAC) is associated with disease-free survival (DFS). Develop and validate an intuitive nomogram based on radiomics signatures, MRI findings, and clinicopathological variables to predict DFS. Methods: Patients (n = 150) from two hospitals who received NAC from August 2011 to May 2017 were diagnosed with TNBC by pathological biopsy, and follow-up through May 2020 was retrospectively analysed. Patients from one hospital (n = 109) were used as the training group, and patients from the other hospital (n = 41) were used as the validation group. ROIs were drawn on 1.5 T MRI T1W enhancement images of the whole volume of the tumour obtained with a 3D slicer. Radiomics signatures predicting DFS were identified, optimal cut-off value for Rad-score was determined, and the associations between DFS and radiomics signatures, MRI findings, and clinicopathological variables were analysed. A nomogram was developed and validated for individualized DFS estimation. Results: The median follow-up time was 53.5 months, and 45 of 150 (30.0%) patients experienced recurrence and metastasis. The optimum cut-off value of the Rad-score was 0.2528, which stratified patients into high- and low-risk groups for DFS in the training group (p<0.001) and was validated in the external validation group. Multivariate analysis identified three independent indicators: multifocal/centric disease status, pCR status, and Rad-score. A nomogram based on these factors showed discriminatory ability, the C-index of the model was 0.834 (95% CI, 0.761–0.907) and 0.868 (95% CI, 0.787–949) in the training and the validation groups, respectively, which is better than clinicoradiological nomogram(training group: C-index = 0.726, 95% CI = 0.709–0.743; validation group: C-index = 0.774,95% CI = 0.743–0.805). Conclusion: The Rad-score derived from preoperative MRI features is an independent biomarker for DFS prediction in patients with TNBC to NAC, and the combined radiomics nomogram improved individualized DFS estimation. |
format | Online Article Text |
id | pubmed-8632946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86329462021-12-02 A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy Xia, Bingqing Wang, He Wang, Zhe Qian, Zhaoxia Xiao, Qin Liu, Yin Shao, Zhimin Zhou, Shuling Chai, Weimin You, Chao Gu, Yajia Front Genet Genetics Background: To investigate whether the radiomics signature (Rad-score) of DCE-MRI images obtained in triple-negative breast cancer (TNBC) patients before neoadjuvant chemotherapy (NAC) is associated with disease-free survival (DFS). Develop and validate an intuitive nomogram based on radiomics signatures, MRI findings, and clinicopathological variables to predict DFS. Methods: Patients (n = 150) from two hospitals who received NAC from August 2011 to May 2017 were diagnosed with TNBC by pathological biopsy, and follow-up through May 2020 was retrospectively analysed. Patients from one hospital (n = 109) were used as the training group, and patients from the other hospital (n = 41) were used as the validation group. ROIs were drawn on 1.5 T MRI T1W enhancement images of the whole volume of the tumour obtained with a 3D slicer. Radiomics signatures predicting DFS were identified, optimal cut-off value for Rad-score was determined, and the associations between DFS and radiomics signatures, MRI findings, and clinicopathological variables were analysed. A nomogram was developed and validated for individualized DFS estimation. Results: The median follow-up time was 53.5 months, and 45 of 150 (30.0%) patients experienced recurrence and metastasis. The optimum cut-off value of the Rad-score was 0.2528, which stratified patients into high- and low-risk groups for DFS in the training group (p<0.001) and was validated in the external validation group. Multivariate analysis identified three independent indicators: multifocal/centric disease status, pCR status, and Rad-score. A nomogram based on these factors showed discriminatory ability, the C-index of the model was 0.834 (95% CI, 0.761–0.907) and 0.868 (95% CI, 0.787–949) in the training and the validation groups, respectively, which is better than clinicoradiological nomogram(training group: C-index = 0.726, 95% CI = 0.709–0.743; validation group: C-index = 0.774,95% CI = 0.743–0.805). Conclusion: The Rad-score derived from preoperative MRI features is an independent biomarker for DFS prediction in patients with TNBC to NAC, and the combined radiomics nomogram improved individualized DFS estimation. Frontiers Media S.A. 2021-11-12 /pmc/articles/PMC8632946/ /pubmed/34868273 http://dx.doi.org/10.3389/fgene.2021.783513 Text en Copyright © 2021 Xia, Wang, Wang, Qian, Xiao, Liu, Shao, Zhou, Chai, You and Gu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Xia, Bingqing Wang, He Wang, Zhe Qian, Zhaoxia Xiao, Qin Liu, Yin Shao, Zhimin Zhou, Shuling Chai, Weimin You, Chao Gu, Yajia A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy |
title | A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy |
title_full | A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy |
title_fullStr | A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy |
title_full_unstemmed | A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy |
title_short | A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy |
title_sort | combined nomogram model to predict disease-free survival in triple-negative breast cancer patients with neoadjuvant chemotherapy |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632946/ https://www.ncbi.nlm.nih.gov/pubmed/34868273 http://dx.doi.org/10.3389/fgene.2021.783513 |
work_keys_str_mv | AT xiabingqing acombinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT wanghe acombinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT wangzhe acombinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT qianzhaoxia acombinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT xiaoqin acombinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT liuyin acombinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT shaozhimin acombinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT zhoushuling acombinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT chaiweimin acombinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT youchao acombinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT guyajia acombinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT xiabingqing combinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT wanghe combinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT wangzhe combinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT qianzhaoxia combinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT xiaoqin combinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT liuyin combinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT shaozhimin combinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT zhoushuling combinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT chaiweimin combinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT youchao combinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy AT guyajia combinednomogrammodeltopredictdiseasefreesurvivalintriplenegativebreastcancerpatientswithneoadjuvantchemotherapy |